C5AR1 and granulomatosis with polyangiitis: Avacopan is a novel, small molecule human C5aR1/CD88 antagonist approved for use in adults with severe, active GPA or MPA in combination with standard therapy including GC according to the FDA [35] or a RTX- or CYC-based regimen according to the EU [36].